首页> 外文期刊>Pharmacology & Pharmacy >Preliminary Study on Counterfeiting of Artemether and Artesunate Marketed in Lubumbashi
【24h】

Preliminary Study on Counterfeiting of Artemether and Artesunate Marketed in Lubumbashi

机译:卢本巴希市售的假冒蒿甲醚和青蒿琥酯的初步研究

获取原文
           

摘要

Pharmaceutical counterfeiting is a health scourge responsible for several cases of morbidity and mortality. Counterfeit medicines cause therapeutic failure, emergence of resistance in the treatment of infections. This study was conducted in order to identify counterfeit and authentic medicines in circulation in Lubumbashi. The study included artemether and artesunate for oral administration. A careful visual inspection of medicine, investigation of authenticity of pharmaceutical products from manufacturers and pharmaceutical regulatory authorities and determination of content were used as study parameters. 52 samples: 37 artemether and 15 of artésunate were collected. 7 samples (13%) have proven to be counterfeit. Artemether was the most counterfeit (71%) and 29% for artesunate. 6 (12%) samples were substandard according to the international pharmacopoeia in terms of content of active ingredient. Sixty-seven percent of non-compliance concerned counterfeit medicines. The proportion of non-compliance is highest among counterfeit medicines (71.43% vs 2.22%; p = 0.000004). It is obvious that strengthening the capacity of the drug regulatory authority of the DRC reduces the influx of counterfeit drug and substandard.
机译:药品造假是一种健康祸害,可导致数例发病和死亡。假药会导致治疗失败,并在感染治疗中产生耐药性。进行这项研究是为了确定卢本巴希正在流通的假冒伪劣药品。该研究包括蒿甲醚和青蒿琥酯口服。仔细的药物外观检查,制造商和药品监管机构对药品真伪的调查以及含量的确定均用作研究参数。 52个样本:收集了37个蒿甲醚和15个蒿甲酸酯。已证明有7个样本(占13%)是伪造的。蒿甲醚是假冒最多的国家(71%),青蒿琥酯为29%。就活性成分含量而言,有6(12%)个样品不符合国际药典的标准。不遵守规定的百分之六十七与假药有关。在假冒药品中,不合规的比例最高(71.43%比2.22%; p = 0.000004)。显然,加强刚果民主共和国药品监管机构的能力可以减少假冒药品和不合格药品的流入。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号